<b>Background/Objectives:</b> Baricitinib, a selective JAK1/JAK2 inhibitor, shows therapeutic potential in psoriasis; however, its oral use is associated with systemic adverse effects, encouraging the development of topical formulations. This evidence concerns the gene JAK2 and psoriasis.